RecruitingPhase 3NCT03773965
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Studying Enthesitis-related juvenile idiopathic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eli Lilly and Company
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, ESTEli Lilly and Company
- Intervention
- Baricitinib(drug)
- Enrollment
- 190 enrolled
- Eligibility
- 1-18 years · All sexes
- Timeline
- 2019 – 2031
Study locations (30)
- Instituto CAICI SRL, Rosario, Argentina
- Centro de Investigaciones Médicas Tucuman, SAN M. de Tucuman, Argentina
- Royal Children's Hospital, Melbourne, Australia
- Perth Children's Hospital, Perth, Australia
- The Children's Hospital at Westmead, Westmead, Australia
- Landeskrankenhaus Bregenz, Bregenz, Austria
- Cliniques universitaires Saint-Luc, Brussels, Belgium
- UZ Gent, Ghent, Belgium
- UZ Leuven, Leuven, Belgium
- Faculdade de Medicina da UNESP, Botucatu, Brazil
- Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
- IPITEC, São Paulo, Brazil
- Universidade Federal de Sao Paulo, São Paulo, Brazil
- Instituto da Crianca do Hospital das Clinicas da FMUSP, São Paulo, Brazil
- Beijing Children's hospital, Capital Medical University, Beijing, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03773965 on ClinicalTrials.govOther trials for Enthesitis-related juvenile idiopathic arthritis
Additional recruiting or active studies for the same condition.
See all trials for Enthesitis-related juvenile idiopathic arthritis →